These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28270510)

  • 1. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via
    Song C; Jung D; Kendi AT; Rho JK; Kim EJ; Horn I; Curran GL; Ghattamaneni S; Shim JY; Kang PS; Kang D; Thakkar JB; Dewan S; Lowe VJ; Lee SB
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
    Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
    Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 represses the molecular phenotype of basal breast cancer cells.
    Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
    Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
    Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
    Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YB-1 interplays with ERα to regulate the stemness and differentiation of ER-positive breast cancer stem cells.
    Yang F; Chen S; He S; Huo Q; Hu Y; Xie N
    Theranostics; 2020; 10(8):3816-3832. PubMed ID: 32206124
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
    Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
    Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
    Madhavan S; Gusev Y; Singh S; Riggins RB
    J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen metabolites treatment promotes ERα+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance.
    Muñoz-Ayala A; Chimal-Vega B; Serafín-Higuera N; Galindo-Hernández O; Ramírez-Rosales G; Córdova-Guerrero I; Gómez-Lucas LF; García-González V
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39034849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
    Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
    Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
    Naderi A; Meyer M; Dowhan DH
    Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
    Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
    Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights into methylation patterns and chromatin accessibility dynamics.
    Nasif D; Laurito S; Real S; Branham MT
    Breast Cancer Res Treat; 2024 Aug; 207(1):91-101. PubMed ID: 38702584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM2 is involved in subtyping and tamoxifen resistance of ERα-positive breast cancer by acting as the downstream factor of ERα.
    Liu S; Liang Z; Wang Y; Ren Y; Gu Y; Qiao Y; He H; Li Y; Cheng Y; Liu Y
    Biotechnol J; 2024 Feb; 19(2):e2300560. PubMed ID: 38403459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells.
    Radde BN; Ivanova MM; Mai HX; Alizadeh-Rad N; Piell K; Van Hoose P; Cole MP; Muluhngwi P; Kalbfleisch TS; Rouchka EC; Hill BG; Klinge CM
    Exp Cell Res; 2016 Sep; 347(1):222-231. PubMed ID: 27515002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
    Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
    Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.
    Wang L; Sun J; Yin Y; Sun Y; Ma J; Zhou R; Chang X; Li D; Yao Z; Tian S; Zhang K; Liu Z; Ma Z
    Cell Death Dis; 2021 Feb; 12(2):149. PubMed ID: 33542201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines-activated nuclear IKKα-FAT10 pathway induces breast cancer tamoxifen-resistance.
    Chen X; Wu W; Jeong JH; Rokavec M; Wei R; Feng S; Schroth W; Brauch H; Zhong S; Luo JL
    Sci China Life Sci; 2024 Jul; 67(7):1413-1426. PubMed ID: 38565741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
    Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.
    Bartoloni S; Pescatori S; Bianchi F; Cipolletti M; Acconcia F
    Sci Rep; 2024 Apr; 14(1):8200. PubMed ID: 38589728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.